发布求助
文献互助 智能选刊 最新文献

Annual Review of Cancer Biology最新文献

筛选
英文 中文
Germline Predisposition to Hematopoietic Malignancies: An Overview 造血恶性肿瘤的基因易感性：概述
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062822-112257
Yogameenakshi Haribabu, Emma Bhote, Lucy A. Godley
{"title":"Germline Predisposition to Hematopoietic Malignancies: An Overview","authors":"Yogameenakshi Haribabu, Emma Bhote, Lucy A. Godley","doi":"10.1146/annurev-cancerbio-062822-112257","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-112257","url":null,"abstract":"Deleterious germline variants are now recognized as common drivers of hematopoietic malignancies (HMs) and bone marrow failure syndromes. With the increasing use of personalized medicine and the application of tumor-based profiling via next-generation sequencing, diagnosis of HM predisposition occurs with increasing frequency. Although deleterious germline variants can be readily identified by comprehensive clinical testing, numerous barriers exist for many clinicians. Observations regarding particular germline predisposition disorders challenge widely held assumptions about these conditions. Here, we review approaches to germline genetic testing, highlighting key points in a typical patient's course that present challenges for testing and interpreting results. Increasing awareness by health care providers of these conditions and improvements in testing platforms are crucial for enabling a proactive approach to tailoring a suitable treatment plan and surveillance program for the patient and their family members.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141522745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins 化学蛋白质组学引导的癌症蛋白质共价配体的发现
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-061421-041946
Xiaoyu Zhang, Benjamin F. Cravatt
{"title":"Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins","authors":"Xiaoyu Zhang, Benjamin F. Cravatt","doi":"10.1146/annurev-cancerbio-061421-041946","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-061421-041946","url":null,"abstract":"Advances in genome sequencing and editing technologies have enriched our understanding of the biochemical pathways that drive tumorigenesis. Translating this knowledge into new medicines for cancer treatment, however, remains challenging, and many oncogenic proteins have proven recalcitrant to conventional approaches for chemical probe and drug discovery. Here, we discuss how innovations in chemical proteomics and covalent chemistry are being integrated to identify and advance first-in-class small molecules that target cancer-relevant proteins. Mechanistic studies have revealed that covalent compounds perturb protein functions in cancer cells in diverse ways that include the remodeling of protein–protein and protein–RNA complexes, as well as through alterations in posttranslational modification. We speculate on the attributes of chemical proteomics and covalent chemistry that have enabled targeting of previously inaccessible cancer-relevant pathways and consider technical challenges that remain to be addressed in order to fully realize the druggability of the cancer proteome.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141522747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Studying Progression from Chronic Injury to Esophageal Adenocarcinoma 研究从慢性损伤到食管腺癌的发展过程
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062822-105541
Thea D. Tlsty
{"title":"Studying Progression from Chronic Injury to Esophageal Adenocarcinoma","authors":"Thea D. Tlsty","doi":"10.1146/annurev-cancerbio-062822-105541","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-105541","url":null,"abstract":"Cancer research seeks to understand the biology underlying the progression to malignant transformation. Recently, the incidence of esophageal adenocarcinoma (EAC) has increased dramatically, and if we understand why and how, we will be better equipped for diagnosis, prognosis, detection, prevention, and intervention. The earliest steps in progression for most malignancies are the most difficult to study. The initiation of cancer is believed to be a relatively rare and sporadic event, the locations and timings of which are most often unknown. Of the trillions of somatic cells in our bodies, only a few ever find themselves on a path to malignancy. However, chronic inflammation generates a metaplastic lesion that is directly linked to increased incidence of EAC and thus alerts us to the time and place that progression is initiated and allows us to study the biology. We describe recent studies that identify coordinated actions between stromal and epithelial cells that progress to EAC.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141522748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histone H3 Variants in the Multiverse of Cancer 癌症多重宇宙中的组蛋白 H3 变异
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062722-021823
Iva Simeonova, Geneviève Almouzni
{"title":"Histone H3 Variants in the Multiverse of Cancer","authors":"Iva Simeonova, Geneviève Almouzni","doi":"10.1146/annurev-cancerbio-062722-021823","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062722-021823","url":null,"abstract":"Our understanding of cancer genomes has allowed for the integration of molecular data into histopathological classifications for routine stratification of patients. In the last 10–15 years, thanks to this systematic implementation of large-scale sequencing, the identification of hotspot somatic mutations in histone genes came into the limelight, underscoring the concept of oncohistones. As drivers in pediatric brain tumors, and in several other types of cancers, oncohistones brought a “new dimension of Strange” into the cancer multiverse, to paraphrase Marvel. An integrative approach to cancer complexity as a multidimensional projection is urgently needed to consider all relevant etiological, developmental, and evolutionary components. Here, we discuss recent progress on histone variants and chaperones, their regulation and alterations in cancers, the available in vivo models, and current treatment strategies. More specifically, we adopt a view through the lens of tissue-specific differences and means for genome expression and integrity maintenance.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141503704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Erratic Path Toward Discovery 通向发现的崎岖之路
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062822-102816
Robert A. Weinberg
{"title":"An Erratic Path Toward Discovery","authors":"Robert A. Weinberg","doi":"10.1146/annurev-cancerbio-062822-102816","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-102816","url":null,"abstract":"Through a series of accidents of history, my career began just when the revolution in molecular biology was taking place. The allure of molecular biology attracted me to exploiting tumor viruses as experimental models of the nucleic acid metabolism of cells. The fact that these viruses cause cancer was incidental but eventually led to an interest in cancer pathogenesis, exploiting them to understand the mechanisms of cell transformation. This made it possible to test the speculation that cell transformation derived from the mutation of cellular genes and that cancer cell behavior is driven by the actions of resulting mutant alleles of these genes. In 1979, we showed that cells that had been transformed by 3-methylcholanthrene carried a mutant oncogenic allele. This work progressed so that by 1982 my research group and others demonstrated that human bladder carcinoma cells carried a point-mutated <jats:italic>RAS</jats:italic> oncogene, providing a direct proof of the mutational theory of cancer pathogenesis.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141503705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer 癌症中的 YAP、TAZ 和希波失调融合蛋白
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-061223-094639
Jordan H. Driskill, Josephine K. Dermawan, Cristina R. Antonescu, Duojia Pan
{"title":"YAP, TAZ, and Hippo-Dysregulating Fusion Proteins in Cancer","authors":"Jordan H. Driskill, Josephine K. Dermawan, Cristina R. Antonescu, Duojia Pan","doi":"10.1146/annurev-cancerbio-061223-094639","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-061223-094639","url":null,"abstract":"Gene fusions are well-known drivers of cancer and are potent targets for molecular therapy. An emerging spectrum of human tumors harbors recurrent and pathognomonic gene fusions that involve the transcriptional coactivator <jats:italic>YAP1</jats:italic> (which encodes the protein YAP) or its paralog <jats:italic>WWTR1</jats:italic> (which encodes the protein TAZ). YAP and TAZ are frequently activated in cancer and are the transcriptional effectors of the Hippo pathway, a highly conserved kinase cascade that regulates diverse functions such as organ size, development, and homeostasis. In this review, we discuss the tumors that have YAP, TAZ, or other Hippo-dysregulating fusion proteins; the mechanisms of these fusion proteins in driving their respective tumors; and the potential vulnerabilities of these chimeric oncoproteins across cancers of many origins. Furthermore, as new <jats:italic>YAP1</jats:italic> and <jats:italic>WWTR1</jats:italic> gene fusions are discovered, we provide a framework to predict whether the resulting protein product is likely to be oncogenic.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141522746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic Rewiring During Metastasis: The Interplay Between the Environment and the Host 转移过程中的代谢重构：环境与宿主之间的相互作用
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062822-122840
Anke Vandekeere, Sarah El Kharraz, Patricia Altea-Manzano, Sarah-Maria Fendt
{"title":"Metabolic Rewiring During Metastasis: The Interplay Between the Environment and the Host","authors":"Anke Vandekeere, Sarah El Kharraz, Patricia Altea-Manzano, Sarah-Maria Fendt","doi":"10.1146/annurev-cancerbio-062822-122840","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-122840","url":null,"abstract":"Following escape from the primary tumor, cancer cells face diverse micro-environments during the metastatic cascade. To survive and establish outgrowth at a distant site, metastasizing cancer cells must undergo metabolic reprogramming to adapt to the changing conditions. However, the host in which the tumors grow also experiences metabolic adaptations in response to various environmental factors that can mediate cancer progression. In this review, we highlight the endogenous factors that determine host metabolism (nutrient availability at specific organs or the microbiome), as well as exogenous factors that influence host metabolism systemically or locally (diet, alcohol, physical activity, air pollution, and circadian rhythm). Furthermore, we elaborate on how these environment-induced metabolic changes can affect metastatic progression. Understanding the interplay between environmental factors, host metabolism, and metastatic progression may unveil potential targets for future therapeutic interventions.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141503702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of Resistance to Targeted Therapies in AML 急性髓细胞性白血病靶向疗法的抗药性机制
Annual Review of Cancer Biology Pub Date : 2024-06-18 DOI: 10.1146/annurev-cancerbio-062822-025055
Matthew F. Jones, Catherine C. Smith
{"title":"Mechanisms of Resistance to Targeted Therapies in AML","authors":"Matthew F. Jones, Catherine C. Smith","doi":"10.1146/annurev-cancerbio-062822-025055","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-025055","url":null,"abstract":"The treatment of acute myeloid leukemia (AML) has historically relied on cytotoxic chemotherapy, but modern understanding of AML biology has paved the way for new treatments that target the molecular pathways that drive AML, in particular FLT3, IDH1/IDH2, and BCL2. Many of these targeted therapies are effective, but responses are typically short-lived and resistance remains a ubiquitous clinical problem. Understanding the mechanisms of resistance to targeted therapy is essential to continue improving AML therapy. Recent studies have shed new light on the ways in which AML evades targeted inhibition, including on-target resistance mutations, mutations in parallel molecular pathways, and plasticity in cellular state. In this review, we outline the mechanisms of resistance to commonly used targeted therapies in AML and discuss ideas to overcome the urgent problem of resistance.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141503703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Intestinal Microbiota and Therapeutic Responses to Immunotherapy 肠道微生物群与免疫疗法的治疗反应
Annual Review of Cancer Biology Pub Date : 2024-01-25 DOI: 10.1146/annurev-cancerbio-062722-035210
Pamela S. Herrera, Marcel van den Brink
{"title":"The Intestinal Microbiota and Therapeutic Responses to Immunotherapy","authors":"Pamela S. Herrera, Marcel van den Brink","doi":"10.1146/annurev-cancerbio-062722-035210","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062722-035210","url":null,"abstract":"The intestinal microbiota, a complex ecosystem of microorganisms, has emerged as an important player in modulating various aspects of human health and disease. The microbiota is in a state of constant cross talk with itself and its host, and these interactions regulate several aspects of host homeostasis, including immune responses. Studies have demonstrated a relationship between the microbiota and outcomes of several cancer immunotherapies. This review explores the different roles of the microbiota in shaping the efficacy and safety of cancer immunotherapies, including allogeneic hematopoietic cell transplantation, immune checkpoint blockade, and CAR T cell therapy.Expected final online publication date for the Annual Review of Cancer Biology, Volume 8 is April 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139589632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Discovery for Chromatin Complexes: Where Do We Stand? 染色质复合物的治疗发现：我们的现状如何？
Annual Review of Cancer Biology Pub Date : 2024-01-12 DOI: 10.1146/annurev-cancerbio-062822-110356
Dominic D.G. Owens, Matthew E.R. Maitland, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy
{"title":"Therapeutic Discovery for Chromatin Complexes: Where Do We Stand?","authors":"Dominic D.G. Owens, Matthew E.R. Maitland, Cheryl H. Arrowsmith, Dalia Barsyte-Lovejoy","doi":"10.1146/annurev-cancerbio-062822-110356","DOIUrl":"https://doi.org/10.1146/annurev-cancerbio-062822-110356","url":null,"abstract":"In this review, we explore the current landscape of preclinical and clinical therapeutics targeting epigenetic complexes in cancer, focusing on targets with enzymatic inhibitors, degraders, or ligands capable of disrupting protein–protein interactions. Current strategies face challenges such as limited single-agent clinical efficacy due to insufficient disruption of chromatin complexes and incomplete dissociation from chromatin. Further complications arise from the adaptability of cancer cell chromatin and, in some cases, dose-limiting toxicity. The advent of targeted protein degradation (TPD) through degrader compounds such as proteolysis-targeting chimeras provides a promising approach. These innovative molecules exploit the endogenous ubiquitin–proteasome system to catalytically degrade target proteins and disrupt complexes, potentially amplifying the efficacy of existing epigenetic binders. We highlight the status of TPD-harnessing moieties in clinical and preclinical development, as these compounds may prove crucial for unlocking the potential of epigenetic complex modulation in cancer therapeutics.Expected final online publication date for the Annual Review of Cancer Biology, Volume 8 is April 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","PeriodicalId":501431,"journal":{"name":"Annual Review of Cancer Biology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139462039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信